Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

68
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromosomal Aberrations in Induced Pluripotent Stem Cells: Identification of Breakpoints in the Large <i>DCC</i> Gene and <i>HIST2</i> Histone Gene Cluster.

International journal of molecular sciences·2025
Same author

Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.

Drug metabolism and personalized therapy·2023
Same author

Non-Covalent Interactions between dUTP C5-Substituents and DNA Polymerase Decrease PCR Efficiency.

International journal of molecular sciences·2023
Same author

Replication stress causes delayed mitotic entry and chromosome 12 fragility at the ANKS1B large neuronal gene in human induced pluripotent stem cells.

Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology·2023
Same author

Genetic markers associated with adverse reactions of radioiodine therapy in thyroid cancer patients.

Drug metabolism and personalized therapy·2023
Same author

Genomic epidemiology of SARS-CoV-2 in Russia reveals recurring cross-border transmission throughout 2020.

PloS one·2023
Same journal

MDMA-induced CYP2D6 inhibition: concentration-dependent variability using dextromethorphan as a probe.

Drug metabolism and personalized therapy·2026
Same journal

Allergic reactions to anaesthetics in surgery: current challenges and perspectives.

Drug metabolism and personalized therapy·2026
Same journal

Superior seizure control with first-line levetiracetam in very low birth weight neonates: a 10-year comparative retrospective study.

Drug metabolism and personalized therapy·2026
Same journal

Allele frequencies of pharmacogenetic biomarkers and genomic ancestry in a sample of the Cuban population.

Drug metabolism and personalized therapy·2026
Same journal

The 10+2 Santorini conference: systems medicine and personalised health therapy. The odyssey from hope to practice: "patient first - <i>keep Ithaca always in your mind</i>" Santorini, Greece, 26-29 May 2026.

Drug metabolism and personalized therapy·2026
Same journal

<i>Drug metabolism and personalized therapy</i> is switching its publication model to open access.

Drug metabolism and personalized therapy·2026
See all related articles

Related Experiment Video

Updated: Nov 11, 2025

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

39.5K

Biochip-based approach for comprehensive pharmacogenetic testing.

Anna Yu Ikonnikova1, Marina A Filippova1, Sergey A Surzhikov1

  • 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.

Drug Metabolism and Personalized Therapy
|March 29, 2021
PubMed
Summary
This summary is machine-generated.

A new biochip enables rapid genetic testing for pharmacogenetic markers, crucial for personalizing drug treatments and preventing adverse reactions in patients with cardiovascular diseases and cancer.

Keywords:
biochipcardiovascular diseasespersonalized therapypharmacogenetic testing

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.4K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.6K

Related Experiment Videos

Last Updated: Nov 11, 2025

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

39.5K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.4K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.6K

Area of Science:

  • Pharmacogenetics
  • Molecular Diagnostics
  • Personalized Medicine

Background:

  • Individual drug response is influenced by genetic factors.
  • Accurate pharmacogenetic profiling is essential for optimizing drug therapy and minimizing adverse drug reactions.
  • Current methods for genotyping multiple pharmacogenetic markers can be time-consuming.

Purpose of the Study:

  • To develop a novel instrument for simultaneous determination of key pharmacogenetic markers.
  • To facilitate personalized treatment strategies, particularly for cardiovascular disease patients.
  • To enable rapid and reliable genetic analysis for a broad range of medications.

Main Methods:

  • Utilized multiplex one-step polymerase chain reaction (PCR).
  • Employed hybridization on a low-density biochip for genotyping.
  • Interrogated 15 polymorphisms across eight critical genes including VKORC1, CYP4F2, GGCX, CYP2C9, CYP2D6, CYP2C19, ABCB1, and SLCO1B1.

Main Results:

  • Genotyped 219 cardiovascular disease (CVD) patients and 48 estrogen receptor (ER)-positive breast cancer (BC) patients.
  • 92.7% of CVD patients possessed one or more actionable risk genotypes affecting drug metabolism (VKORC1, CYP2C9, CYP2C19, SLCO1B1, CYP2D6).
  • 25% of ER-positive BC patients were identified as CYP2D6 intermediate or poor metabolizers.

Conclusions:

  • The developed biochip provides a rapid and robust method for genotyping essential pharmacogenetic markers.
  • This technology supports optimized drug selection and dosage adjustments to prevent adverse drug reactions.
  • Applicable across multiple clinical fields including cardiology, oncology, psychiatry, rheumatology, and gastroenterology.